Bart de Keizer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5396980/publications.pdf

Version: 2024-02-01

101384 174990 3,560 140 36 52 citations h-index g-index papers 145 145 145 4249 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Quantitative Comparison of PET and Bremsstrahlung SPECT for Imaging the In Vivo Yttrium-90 Microsphere Distribution after Liver Radioembolization. PLoS ONE, 2013, 8, e55742.	1.1	162
2	FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 565-574.	3.3	135
3	Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?. Annals of Oncology, 2014, 25, 921-927.	0.6	113
4	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 749-755.	3.3	104
5	Opportunistic screening for osteoporosis on routine computed tomography? An external validation study. European Radiology, 2015, 25, 2074-2079.	2.3	100
6	Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. European Radiology, 2014, 24, 1153-1165.	2.3	96
7	Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. European Journal of Endocrinology, 2005, 152, 33-37.	1.9	93
8	Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbeck's Archives of Surgery, 2016, 401, 925-935.	0.8	85
9	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Journal of Urology, 2020, 203, 537-545.	0.2	79
10	Not the Number but the Location of Lymph Nodes Matters for Recurrence Rate and Diseaseâ€Free Survival in Patients with Differentiated Thyroid Cancer. World Journal of Surgery, 2012, 36, 1262-1267.	0.8	78
11	The tubarial salivary glands: A potential new organ at risk for radiotherapy. Radiotherapy and Oncology, 2021, 154, 292-298.	0.3	77
12	¹⁸ F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology, 2017, 284, 460-467.	3.6	73
13	Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT–CT, ultrasound and first results of 18F-fluorocholine PET–CT. European Journal of Radiology, 2015, 84, 1745-1751.	1.2	68
14	Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging. Nuclear Medicine Communications, 2016, 37, 1246-1252.	0.5	64
15	Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 367-373.	3.3	62
16	Accuracy of bone mineral density quantification using dual-layer spectral detector CT: a phantom study. European Radiology, 2017, 27, 4351-4359.	2.3	60
17	Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 125, 478-486.	0.2	58
18	Qualitative elastography can replace thyroid nodule fine-needle aspiration in patients with soft thyroid nodules. A systematic review and meta-analysis. European Journal of Radiology, 2015, 84, 652-661.	1.2	57

#	Article	IF	CITATIONS
19	Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. European Journal of Radiology, 2017, 88, 117-128.	1.2	56
20	Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. European Journal of Cancer, 2020, 124, 47-55.	1.3	55
21	Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands. EJNMMI Research, 2018, 8, 56.	1.1	54
22	Elective Neck Dissection or Sentinel Lymph Node Biopsy in Early Stage Oral Cavity Cancer Patients: The Dutch Experience. Cancers, 2020, 12, 1783.	1.7	50
23	Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nuclear Medicine Communications, 2000, 21, 529-532.	0.5	49
24	The Role of Routine Diagnostic Radioiodine Whole-Body Scintigraphy in Patients with High-Risk Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2011, 52, 56-59.	2.8	48
25	High Failure Rates After 131I Therapy in Graves Hyperthyroidism Patients With Large Thyroid Volumes, High Iodine Uptake, and High Iodine Turnover. Clinical Nuclear Medicine, 2013, 38, 401-406.	0.7	48
26	Differential FDG-PET Uptake Patterns in Uninfected and Infected Central Prosthetic Vascular Grafts. European Journal of Vascular and Endovascular Surgery, 2015, 50, 376-383.	0.8	48
27	Thyroid Ultrasound-Guided Fine-Needle Aspiration: The Positive Influence of On-Site Adequacy Assessment and Number of Needle Passes on Diagnostic Cytology Rate. Acta Cytologica, 2016, 60, 39-45.	0.7	46
28	Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). Journal of Clinical Oncology, 2020, 38, 3377-3387.	0.8	46
29	68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617. EJNMMI Research, 2020, 10, 18.	1.1	46
30	Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 198-202.	2.2	45
31	Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. European Radiology, 2013, 23, 2271-2278.	2.3	44
32	Modest utility of quantitative measures in 18 F-fluorodeoxyglucose positron emission tomography scanning for the diagnosis of aorticâprosthetic graft infection. Journal of Vascular Surgery, 2015, 61, 965-971.	0.6	44
33	Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. Journal of Nuclear Medicine, 2004, 45, 1549-54.	2.8	42
34	Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-ï»; a preliminary analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1614-1621.	3.3	41
35	Wholeâ€body MRIâ€DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study. Journal of Magnetic Resonance Imaging, 2015, 42, 1646-1655.	1.9	39
36	124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). Journal of Nuclear Medicine, 2016, 57, 701-707.	2.8	39

#	Article	IF	CITATIONS
37	Dose–Response and Dose–Toxicity Relationships for Glass ⁹⁰ Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. Journal of Nuclear Medicine, 2021, 62, 1616-1623.	2.8	36
38	Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Ecological Management and Restoration, 2018, 31, .	0.2	31
39	Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget, 2019, 10, 4149-4160.	0.8	31
40	Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments. Journal of Personalized Medicine, 2021, 11, 270.	1.1	31
41	Depth of invasion in patients with early stage oral cancer staged by sentinel node biopsy. Head and Neck, 2019, 41, 2100-2106.	0.9	30
42	Sentinel lymph node detection in oral cancer: a within-patient comparison between [99mTc]Tc-tilmanocept and [99mTc]Tc-nanocolloid. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 851-858.	3.3	28
43	The use of 18F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. Journal of Neuro-Oncology, 2015, 125, 167-175.	1.4	27
44	European guideline for imaging in paediatric and adolescent rhabdomyosarcoma — joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology. Pediatric Radiology, 2021, 51, 1940-1951.	1.1	27
45	What is the role of sentinel lymph node biopsy in the management of oral cancer in 2020?. European Archives of Oto-Rhino-Laryngology, 2021, 278, 3181-3191.	0.8	27
46	Quantitative Comparison of ¹²⁴ I PET/CT and ¹³¹ I SPECT/CT Detectability. Journal of Nuclear Medicine, 2016, 57, 103-108.	2.8	26
47	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. Head and Neck, 2017, 39, 2329-2349.	0.9	26
48	New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma. Cancers, 2020, 12, 3055.	1.7	26
49	Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer, 2020, 20, 519.	1.1	25
50	Interobserver Agreement of Interim and End-of-Treatment ¹⁸ F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. Journal of Nuclear Medicine, 2018, 59, 1831-1836.	2.8	23
51	High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment. Oral Oncology, 2019, 94, 68-72.	0.8	23
52	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. Journal of Nuclear Medicine, 2019, 60, 1111-1117.	2.8	23
53	New national recommendations for the treatment of pediatric differentiated thyroid carcinoma in the Netherlands. European Journal of Endocrinology, 2020, 183, P11-P18.	1.9	23
54	First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. Clinical Nuclear Medicine, 2019, 44, 446-451.	0.7	22

#	Article	IF	CITATIONS
55	Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study. BMC Cancer, 2014, 14, 405.	1.1	21
56	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatric Blood and Cancer, 2020, 67, e28061.	0.8	21
57	Use of C-Arm Cone Beam CT During Hepatic Radioembolization: Protocol Optimization for Extrahepatic Shunting and Parenchymal Enhancement. CardioVascular and Interventional Radiology, 2016, 39, 64-73.	0.9	20
58	A phantom study: Should ¹²⁴ lâ€mlBG PET/CT replace ¹²³ lâ€mlBG SPECT/CT?. Medical Physics, 2017, 44, 1624-1631.	1.6	19
59	Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. EJNMMI Research, 2019, 9, 69.	1.1	19
60	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	2.0	19
61	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2174-2188.	3.3	19
62	Identifying Aberrant Hepatic Arteries Prior to Intra-arterial Radioembolization. CardioVascular and Interventional Radiology, 2014, 37, 1482-1493.	0.9	18
63	Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma. Acta Radiologica, 2016, 57, 142-151.	0.5	18
64	Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer. Endocrine Research, 2017, 42, 302-310.	0.6	17
65	68Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma. Nuclear Medicine and Molecular Imaging, 2017, 51, 360-361.	0.6	17
66	Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study. European Radiology, 2021, 31, 1494-1504.	2.3	17
67	CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 481-491.	3.3	17
68	Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study Journal of Clinical Oncology, 2016, 34, 7504-7504.	0.8	17
69	Current Status and Future Direction of Hepatic Radioembolisation. Clinical Oncology, 2021, 33, 106-116.	0.6	16
70	[68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy: a novel technique for sentinel lymph node imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 963-965.	3.3	15
71	The Added Value of [18F]FDG PET/CT in the Management of Invasive Fungal Infections. Diagnostics, 2021, 11, 137.	1.3	15
72	First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Research, 2021, 11, 126.	1.1	15

#	Article	IF	Citations
73	The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer. Human Pathology, 2018, 81, 245-254.	1.1	14
74	Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization—a prospective, within-patient randomized study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1658-1668.	3.3	13
75	Intraarterial Administration Boosts ¹⁷⁷ Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. Journal of Nuclear Medicine, 2022, 63, 406-409.	2.8	13
76	PET Molecular Targets and Near-Infrared Fluorescence Imaging of Atherosclerosis. Current Cardiology Reports, 2018, 20, 11.	1.3	12
77	Contralateral Regional Recurrence in Lateralized or Paramedian Early-Stage Oral Cancer Undergoing Sentinel Lymph Node Biopsy—Comparison to a Historic Elective Neck Dissection Cohort. Frontiers in Oncology, 2021, 11, 644306.	1.3	12
78	¹⁸ F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. Journal of Nuclear Medicine, 2022, 63, 1001-1007.	2.8	12
79	Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients. Acta Oncológica, 2018, 57, 1687-1692.	0.8	11
80	Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial). Clinical Nuclear Medicine, 2019, 44, 272-275.	0.7	11
81	Feasibility of sentinel node navigated surgery in high-risk T1b esophageal adenocarcinoma patients using a hybrid tracer of technetium-99Âm and indocyanine green. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 2671-2679.	1.3	11
82	High FDG Uptake in the Right Ventricular Myocardium of a Pulmonary Hypertension Patient. Journal of the American College of Cardiology, 2013, 62, 1724.	1.2	10
83	The tubarial glands paper: A starting point. A reply to comments. Radiotherapy and Oncology, 2021, 154, 308-311.	0.3	10
84	Whole-body MRI versus an [18F]FDG-PET/CT-based reference standard for early response assessment and restaging of paediatric Hodgkin's lymphoma: a prospective multicentre study. European Radiology, 2021, 31, 8925-8936.	2.3	10
85	Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 231-8.	1.0	10
86	Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis. Biomedicines, 2022, 10, 1575.	1.4	10
87	SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. Endocrine, 2018, 62, 639-647.	1.1	9
88	Persistent Disease in Patients with Papillary Thyroid Carcinoma and Lymph Node Metastases After Surgery and Iodineâ€131 Ablation. World Journal of Surgery, 2007, 31, 2309-2314.	0.8	8
89	I-131 Accumulation in a Benign Cystic Mesothelioma in a Patient with Follicular Thyroid Cancer. Thyroid, 2008, 18, 369-371.	2.4	8
90	18F-Fluorocholine PET–CT enables minimal invasive parathyroidectomy in patients with negative sestamibi SPECT–CT and ultrasound: A case report. International Journal of Surgery Case Reports, 2015, 13, 73-75.	0.2	8

#	Article	IF	Citations
91	Lutetium-177-PSMA therapy for prostate cancer patients—aÂbrief overview of the literature. Tijdschrift Voor Urologie, 2020, 10, 141-146.	0.1	8
92	Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. Cancers, 2022, 14, 781.	1.7	8
93	Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 399-409.	0.9	7
94	New Insights in Resistance to Interchange. Transportation Research Procedia, 2015, 8, 72-79.	0.8	7
95	Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. The Cochrane Library, 2021, 2021, CD012325.	1.5	7
96	To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	3.3	7
97	Calibration of PET/CT scanners for multicenter studies on differentiated thyroid cancer with 124I. EJNMMI Research, 2016, 6, 39.	1.1	6
98	PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy. Molecular Imaging, 2020, 19, 153601212093499.	0.7	6
99	High CXCR4 expression in adenoid cystic carcinoma of the head and neck is associated with increased risk of locoregional recurrence. Journal of Clinical Pathology, 2020, 73, 476-482.	1.0	6
100	Diagnostic accuracy of [^{99m} Tc]Tcâ€tilmanocept compared to [^{99m} Tc]Tcâ€nanocolloid for sentinel lymph node identification in earlyâ€stage oral cancer. Clinical Otolaryngology, 2021, 46, 1383-1388.	0.6	6
101	Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	3.3	6
102	Urothelial carcinoma in an orthotopic neobladder: an unusual pattern of recurrence and metastasis. BMJ Case Reports, 2017, 2017, bcr-2017-221052.	0.2	5
103	Gastrointestinal stromal tumour detection with somatostatin receptor imaging, 68Ga-HA-DOTATATE PET–CT. Lancet Oncology, The, 2017, 18, e185.	5.1	4
104	Fused high b-value diffusion weighted and T2-weighted MR images in staging of pediatric Hodgkin's lymphoma: A pilot study. European Journal of Radiology, 2019, 121, 108737.	1.2	4
105	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	3.3	4
106	A Rapid and Safe Infusion Protocol for ¹⁷⁷ Lu Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2021, 62, 816-822.	2.8	4
107	FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels. European Journal of Endocrinology, 2022, 187, 101-110.	1.9	4
108	Potential Clinical Applications of PET/Magnetic Resonance Imaging. PET Clinics, 2013, 8, 367-384.	1.5	3

#	Article	IF	CITATIONS
109	False-positive PET scan after bone marrow biopsy. British Journal of Haematology, 2013, 161, 753-753.	1.2	3
110	The role of qualitative elastography in thyroid nodule evaluation: exploring its target populations. Endocrine, 2015, 50, 265-267.	1.1	3
111	⁸⁹ Zrâ€rituximab PET/CT to detect neurolymphomatosis. American Journal of Hematology, 2016, 91, 649-650.	2.0	3
112	New Developments in Sentinel Lymph Node Biopsy Procedure in Localized Oral Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 741.	1.2	3
113	Zirconium-89 labelled rituximab PET-CT imaging of Graves' orbitopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 738-739.	3.3	3
114	[68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy for sentinel lymph node detection in early-stage oral cavity carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1246-1247.	3.3	3
115	The prognostic impact of micrometastases and isolated tumor cells in early oral squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2021, 278, 5105-5106.	0.8	3
116	Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study Journal of Clinical Oncology, 2019, 37, 7507-7507.	0.8	3
117	Breast cancer sentinel node scintigraphy. Nuclear Medicine Communications, 2012, 33, 1138-1143.	0.5	2
118	Detection of Synchronous Parathyroid Adenoma and Breast Cancer with 18F-Fluorocholine PET-CT. Nuclear Medicine and Molecular Imaging, 2016, 50, 180-182.	0.6	2
119	Letter to the Editor Regarding the Article " ¹²⁴ I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis― Thyroid, 2016, 26, 1141-1142.	2.4	2
120	Is there a place for FDG-PET-CT in early oral cancer patients?. Oral Oncology, 2018, 84, 123-124.	0.8	2
121	Competition (â€~Steal' Phenomenon) between [68Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue. Pharmaceutics, 2021, 13, 699.	2.0	2
122	Increased vascular inflammation on PET/CT in psoriasis and the effects of biologic treatment: systematic review and meta-analyses. Clinical and Translational Imaging, 2022, 10, 225-235.	1.1	2
123	Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection. Nuklearmedizin - NuclearMedicine, 2009, 48, 26-9.	0.3	2
124	Within-patient comparison between [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [99mTc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2023-2036.	3.3	2
125	Reply: THYROPET Study: Is It Biology or Technology That Is the Issue?. Journal of Nuclear Medicine, 2017, 58, 354.2-355.	2.8	1
126	RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY. Hematological Oncology, 2019, 37, 79-80.	0.8	1

#	Article	IF	Citations
127	Detection of sentinel lymph nodes by tilmanocept in oral squamous cell carcinoma. Clinical and Experimental Metastasis, 2022, 39, 417-419.	1.7	1
128	FDG-PET combined with CT considerably alters tumour delineation for radiotherapy for h&n cancer compared to CT only. Radiotherapy and Oncology, 2007, 82, S6.	0.3	0
129	Reply: Utility of Diagnostic Whole-Body Iodine Scanning in High-Risk Differentiated Thyroid Carcinoma. Journal of Nuclear Medicine, 2012, 53, 662-663.	2.8	0
130	OC-007: Sentinel node biopsy for early stage oral cancer; experience of 2 Dutch head and neck centers. Radiotherapy and Oncology, 2017, 122, 7.	0.3	0
131	FDGâ€PET as a Biomarker of Response in DLBCL: the HOVON 84 Study Experience. Hematological Oncology, 2017, 35, 40-41.	0.8	0
132	OC-020 Sentinel lymph node biopsy for early stage oral cancer; experience of 3 Dutch Head and Neck centers. Radiotherapy and Oncology, 2019, 132, 12-13.	0.3	0
133	OC-022 Unexpected drainage patterns and high accuracy of SLNB in OSCC after previous neck treatment. Radiotherapy and Oncology, 2019, 132, 13-14.	0.3	0
134	S1599 RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B ELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVONâ€NORDIC LYMPHOMA GROUP PHASE III STUDY. HemaSphere, 2019, 3, 736.	1,2	0
135	Sa1235 FEASIBILITY OF SENTINEL NODE NAVIGATION SURGERY IN PATIENTS WITH HIGH-RISK SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA USING A HYBRID TRACER OF TECHNETIUM-99M AND INDOCYANINE GREEN. Gastrointestinal Endoscopy, 2020, 91, AB123-AB124.	0.5	0
136	Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients. Cancer, 2021, 127, 1959-1962.	2.0	0
137	Holmium-166 Radioembolization. Digestive Disease Interventions, 0, 05, .	0.3	0
138	Evaluation of a streamlined sentinel lymph-node imaging protocol in early-stage oral cancer. Annals of Nuclear Medicine, 2021, 35, 1353-1360.	1.2	0
139	High Negative Predictive Value (NPV) Of Undetectable TSH Stimulated Tg For Disease Recurrence In Both Low And High Risk Differentiated Thyroid Cancer. Journal of Thyroid Disorders & Therapy, 2014, 03, .	0.1	0
140	FEASIBILITY OF SENTINEL NODE NAVIGATED SURGERY IN PATIENTS WITH HIGH-RISK SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA USING A HYBRID TRACER OF TECHNETIUM-99M AND INDOCYANINE GREEN. Endoscopy, 2020, 52, .	1.0	O